We are happy to be able to provide you with SPRAVATO® (esketamine) CIII, a nasal spray that can be taken with an oral antidepressant to treat treatment-resistant depression (TRD) in adults and depressive symptoms in adults with MDD with acute suicidal ideation or behavior.
Speak with your Prescriber to see if Spravato is right for you.
-
SPRAVATO® is a prescription medicine, used along with an antidepressant taken by mouth to treat Depressive symptoms in adults with major depressive disorder (MDD) with suicidal thoughts or actions.
SPRAVATO® offers a different approach and is the only nasal spray treatment indicated for treatment-resistant depression (TRD).
SPRAVATO® is the only FDA-approved nasal spray for TRD.
SPRAVATO® is an NMDA receptor antagonist that is believed to work differently by acting on a pathway in the brain that affects glutamate.
The exact way SPRAVATO® works is not fully understood
Limitations of Use:
SPRAVATO® is not for use as a medicine to prevent or relieve pain (anesthetic). It is not known if SPRAVATO® is safe or effective as an anesthetic medicine.
It is not known if SPRAVATO® is safe and effective for use in preventing suicide or in reducing suicidal thoughts or actions. SPRAVATO® is not for use in place of hospitalization if your healthcare provider determines that hospitalization is needed, even if improvement is experienced after the first dose of SPRAVATO®.
It is not known if SPRAVATO® is safe and effective in children.
-
If you’ve taken two or more oral antidepressants and still experience symptoms of depression, you might have treatment-resistant depression(TRD).
It might be time to talk to your doctor about a different treatment approach. See what makes SPRAVATO® different and learn more about other patients’ experiences with SPRAVATO®.
Click HERE to learn more.
-
-
If you have treatment-resistant depression (TRD), you may benefit from adding SPRAVATO® to your current oral antidepressant.
Call our office to see if adding SPRAVATO® may be right for you, and discover more about what the full SPRAVATO® treatment experience could look like for you.
-
There is a study that suggests after the third oral antidepressant, remission rates dropped below 14%. If you’ve tried two or more oral antidepressants and are still experiencing depressive symptoms, you may have treatment-resistant depression and it may be time for something different.
-
Treatment-resistant depression is defined as not responding to two or more antidepressants of adequate dose and duration. If your doctor has diagnosed you with treatment-resistant depression, you may benefit from treatment with a different kind of medication.
-
It is helpful to understand the clinical trials for any medication you consider taking.
-
It is important to understand the potential side effects of any medication you consider taking. To help ensure safety, SPRAVATO® is available only through a restricted distribution program called the SPRAVATO® Risk Evaluation and Mitigation Strategy (REMS) Program.
-
Yes. Dagenhart Health and Wellness is a certified SPRAVATO® treatment center.
SPRAVATO® is only available at certified treatment centers and must be self-administered under the supervision of a healthcare provider.
-
Cost can sometimes impact a patient’s treatment journey; however, there may be affordability programs available to help eligible patients.
Click HERE for additional information.
